BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25236571)

  • 21. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma.
    Pedace L; De Simone P; Castori M; Sperduti I; Silipo V; Eibenschutz L; De Bernardo C; Buccini P; Moscarella E; Panetta C; Ferrari A; Grammatico P; Catricalà C
    Cancer Epidemiol; 2011 Dec; 35(6):e116-20. PubMed ID: 21893440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
    Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation screening of the CDKN2A promoter in melanoma families.
    Harland M; Holland EA; Ghiorzo P; Mantelli M; Bianchi-Scarrà G; Goldstein AM; Tucker MA; Ponder BA; Mann GJ; Bishop DT; Newton Bishop J
    Genes Chromosomes Cancer; 2000 May; 28(1):45-57. PubMed ID: 10738302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple primary melanoma revisited.
    Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A
    Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
    Goldstein AM
    Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LINE-1 hypomethylation and mutational status in cutaneous melanomas.
    Pramio DT; Pennacchi PC; Maria-Engler SS; Campos AH; Duprat JP; Carraro DM; Krepischi AC
    J Investig Med; 2016 Apr; 64(4):899-904. PubMed ID: 26965315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline melanoma susceptibility and prognostic genes: a review of the literature.
    Ward KA; Lazovich D; Hordinsky MK
    J Am Acad Dermatol; 2012 Nov; 67(5):1055-67. PubMed ID: 22583682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKN2A mutations in melanoma families from Uruguay.
    Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
    Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the CDKN2A locus in patients with multiple primary melanomas.
    Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
    J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil.
    Bakos RM; Besch R; Zoratto GG; Godinho JM; Mazzotti NG; Ruzicka T; Bakos L; Santos SE; Ashton-Prolla P; Berking C; Giugliani R
    Exp Dermatol; 2011 Nov; 20(11):890-3. PubMed ID: 21895773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
    van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutional promoter methylation and risk of familial melanoma.
    Hyland PL; Burke LS; Pfeiffer RM; Rotunno M; Sun D; Patil P; Wu X; Tucker MA; Goldstein AM; Yang XR
    Epigenetics; 2014 May; 9(5):685-92. PubMed ID: 24762620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic mutations in CDKN2A in western Swedish families with hereditary malignant melanoma.
    Erlandson A; Appelqvist F; Enerbäck C
    Mol Med Rep; 2008; 1(1):89-91. PubMed ID: 21479383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.